期刊
THROMBOSIS AND HAEMOSTASIS
卷 107, 期 5, 页码 838-847出版社
GEORG THIEME VERLAG KG
DOI: 10.1160/TH11-10-0718
关键词
Dabigatran; atrial fibrillation; oral anticoagulant; bleeding
资金
- Boehringer Ingelheim
- Bayer Healthcare
- Pfizer
- GSK
- Actelion
- AstraZeneca
- Lundbeck
- Novartis
- Janssen-Cilag
- Sanofi-Aventis
- Syngis
- Talecris
- German Research Council (DFG)
- German Ministry of Education and Research (BMBF)
- European Union
- National Institute of Health
- Bertelsmann Foundation
- Heinz-Nixdorf Foundation
Dabigatran etexilate is a new oral anticoagulant recently approved in Europe for the prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. With a fast onset of action and a predictable anticoagulant effect obviating the need for coagulation monitoring, dabigatran etexilate offers practical advantages over vitamin K antagonists in clinical practice. However, clinicians may have questions about practical aspects of dabigatran etexilate use including monitoring anticoagulant efficacy, interruption for surgical or invasive procedures and management of bleeding. This review article aims to address these concerns and provide guidance on the use of dabigatran etexilate in special situations, such as acute coronary syndromes and cardiac revascularisation. In addition, cut-off values for different coagulation assay results associated with an increased risk of bleeding are given.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据